News Column

Brainstorm Cell Therapeutics Inc. Files SEC Form 424B3, Prospectus [Rule 424(B)(3)] (Aug. 27, 2014)

September 8, 2014

By a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Brainstorm Cell Therapeutics Inc. (Form 424B3) was posted on August 27, 2014.

The SIC code for this company is 2836, Biological Products, (No Diagnostic Substances).

There was one document filed with this form. The SEC file number is 0001144204-14-052675.

The contact information for this company is 605 THIRD AVENUE, 34TH FLOOR, NEW YORK NY 10158, 646-666-3188.

Our editors provided additional information about Form 424B3: Final prospectus filed pursuant to Rule 424(b)(3).

A U.S. Securities and Exchange Commission filing is a formal document or financial statement submitted to the SEC by publicly-traded companies.

For additional information on this SEC filing see:

Keywords for this news article include: (No Diagnostic Substances), Biological Products, Biological Therapy, Biotechnology Companies, Biotechnology Company, BrainStorm Cell Therapeutics, Brainstorm Cell Therapeutics Inc., Pharmaceutical Companies, Pharmaceutical Company, SEC Filing.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Pharma Business Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters